BV6 increases bone metastasis.

Slides:

Advertisements

Similar presentations

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Advertisements

Binding of 53BP1 on uncapped telomeres.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Fig. 8. In vivo suppression of MM by CMLD

BV6 increases tumor burden in bone.

Validation of St6GalNAc2 as a metastasis suppressor gene.

Yong-jiang Hei European Urology Supplements

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

COX-2–PGE2 signaling is required for MSC-induced increase in ALDHhigh CSC-enriched population and tumor initiation. COX-2–PGE2 signaling is required for.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Preclinical Profile of Zoledronic Acid in Prostate Cancer Models

Bioluminescence imaging facilitates detection of tumor growth and metastasis in mouse orthotopic xenograft model. Bioluminescence imaging facilitates detection.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Vaccine MN confer protective innate and adaptive immunity.

Effects of rhein on FBG (A) and glucose intolerance (B) in db/db mice.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

Antitumor immunity caused by DS-8201a.

Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.

Effect of HA on hematopoietic recovery in tumor-bearing mice.

coTCRcys-transduced T cells control tumor growth in vivo.

The selective depletion of DTR-expressing FAP+/CD45+ and FAP+/CD45− tumoral cells from bone marrow chimeric mice by the administration of DTX. A, sketch.

Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but not OVA Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but.

EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,

In vivo growth-inhibitory effect of perifosine on bevacizumab-resistant CCC. A, the effect of bevacizumab (BEV) on CCC growth in vivo. In vivo growth-inhibitory.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

H19 was essential for cancer metastasis.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.

Active AR signaling in enzalutamide-resistant xenograft tumors.

Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.

IDO deficiency delays the development of pulmonary metastases.

Induction of a tumor-specific immune response following radiofrequency ablation (RFA). Induction of a tumor-specific immune response following radiofrequency.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)

Rif/mDia2 signaling in primary tumor formation and spontaneous metastasis. Rif/mDia2 signaling in primary tumor formation and spontaneous metastasis. A,

GM-CSF is required for CA-MSC–induced tumor metastasis.

Essential role for the overexpression of type I IFN-related genes in the improved chemotherapeutic response of Stat3−/− tumors. Essential role for the.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

Deletion of Tgfbr2 in myeloid cells elevated IFN-γ production in CD8+ T cells, and systemic IFN-γ neutralization diminished metastasis inhibition in Tgfbr2MyeKO.

CD44 depletion blocks tumor cell aggregation and lung metastasis in vivo. CD44 depletion blocks tumor cell aggregation and lung metastasis in vivo. A,

The CD8+ cytotoxic T-cell response in Ron TK−/− hosts in response to tumors is necessary and sufficient to block metastasis. The CD8+ cytotoxic T-cell.

Mean cell number in small intestinal crypt (a), small intestinal villus (b), and midcolonic crypt (c) of BALB/c (♦) and DBA/2 (▪) mice after two injections.

In vivo bioluminescence imaging of primary tumors and tumor metastasis

Ex vivo imaging of lymph nodes with tumor metastasis using a bioluminescence imaging system. Ex vivo imaging of lymph nodes with tumor metastasis using.

A and B, intratumoral DC-AdCCL21 leads to reduction in growth rates of bilateral tumors. A and B, intratumoral DC-AdCCL21 leads to reduction in growth.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

YH25448 less suppresses WT EGFR than osimertinib in vivo.

Mean weight change from original weight of (a) BALB/c (b) DBA/2 mice after one (♦) or two (▴) injections of 10 mg/kg and one (▪) or two (×) injections.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

MDSC-derived IL-6 enhances tumor progression through the inhibition of tumor-specific TH1 development and of their helper activity for CD8+ T cells. MDSC-derived.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

SPARC is required for spontaneous metastasis

Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth. Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

PDL192 and inhibit the growth of xenograft tumors.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

Effects of ZOL treatment on pulmonary metastases.

Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor cells after weekly CAR+ T-cell treatment for 4 wks. Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor.

GCS-100 selectively kills KRAS-addicted lung tumors.

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

Ex vivo profiling of PD-1 blockade using MDOTS

In vivo shRNA screening strategy.

AXL knockout does not prevent dormancy.

DHA and dietary n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in xenograft models. DHA and dietary n-3 PUFAs inhibit endometrial cancer.

Presentation transcript:

BV6 increases bone metastasis. BV6 increases bone metastasis. A, scheme of tumor inoculation. BALB/c mice were treated with BV6 (10 mg/kg) and zoledronic acid (40 μg/kg) weekly for 4 weeks, and 1 × 105 4T1-Fluc cells were injected into left ventricles when mice were 6 weeks old. Vehicle, n = 15; vehicle + zoledronic acid, n = 12; BV6, n = 9; BV6 + zoledronic acid, n = 9. B, bioluminescence signals were measured on days 7, 10, and 13 after tumor inoculation. Signals from both hind legs and mandibles were summed. C, representative images of B on day 13 are shown. D, incidence of metastases was calculated from tumor growth sites on hind legs and mandibles of each mouse. E, femurs were scanned with μCT to measure BV/TV. F, representative photos of E are shown. Data represent the mean ± SD; n.s., not significant. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ZA, zoledronic acid. Chang Yang et al. Cancer Discovery 2013;3:212-223 ©2013 by American Association for Cancer Research